IRCCS National Cancer Institute "Regina Elena"
Rome, 00144, Italy
Location status: Recruiting
NCT Number: NCT06878027
Multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially available tests (e.g. BladderCARE, Bladder EpiCheck), to apply and validate tests based on targeted multi-marker or genome wide analyzes via NGS and to identify methylation profiles as a tool to infer clinical outcome.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Rome, 00144, Italy
Location status: Recruiting
The study has the primary objective to investigate the diagnostic capacity of methylation levels in urine samples, furthermore it has the secondary objective of applying an NGS test on the urine sample capable of evaluating the highest methylation levels comprehensive, with better analytical performance than the currently available standard on the market, leveraging targeted sequencing of multiple genes or global analysis of the whole methylome.
To describe the diagnostic performance of the methods in a real-world clinical environment and identify the characteristic methylation profiles capable of stratifying patients with different prognoses, and finally to explore the potential economic impact of applying such tests as tools alternatives to conventional practices.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patient group
group of healthy subjects
Exclusion criteria
Patient group
group of healthy subjects
Time frame: 18 months
Measurement of methylation status using the Bladder CARE test (Pangea Laboratory LLC). The test, based on quantitative PCR and evaluation of methylation status in 3 target genes, is performed on a urine sample and has reported high sensitivity (94%) and specificity (93%) values in determining the presence of bladder cancer
Contact information is provided by the study sponsor or research team.
Regina Elena Cancer Institute
Other
Analysis of Urinary Methylation Patterns Via Liquid Biopsy as a Tool for Early Diagnosis, Non-invasive Monitoring and Prediction of Recurrence Risk in Bladder Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06963346
Bladder Cancer, Female Urogenital Diseases
Tampa, Florida, United States
View Trial DetailsNCT07660055
Bladder Cancer, Breast Cancer
Darlinghurst, New South Wales, Australia
View Trial DetailsNCT07419295
Bladder Cancer, Female Urogenital Diseases
Traverse City, Michigan, United States
View Trial DetailsNCT06465069
Adnexal Diseases, Advanced Solid Tumor
Duarte, California, United States
View Trial Details